

PTO/SB/08A (10-96)  
 Approved for use through 10/31/99. OMB 0651-0031  
 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
 Collection of information does not contain a valid OMB control number.

+ #8

**Complete if Known**

Application Number	N/A 09/989, 545
Filing Date	11/21/2001
First Named Inventor	Sophie Lehar et al
Group Art Unit	1644
Examiner Name	Ilia Dneprenski
Attorney Docket Number	MPI1998-067CP2CN1A(M)

Sheet 1 of 1

U.S. PTO  
89/089815

[illegible]

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>8</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
I.O.	2	WO	98/38216		Japan Tobacco Inc.	03/09/1998	/	
	3	WO	98/39448		Human Genome Sci	09/11/1998		
	4	WO	98/45437		Genetics Institute	10/15/1998		
	5	WO	99/07727		Mass Inst of Techn	02/18/1999		
	6	WO	99/09049		Quark Biotech, Inc	02/25/1999		
	7	WO	99/46281		Genentech, Inc.	09/16/1999		
I.O.	8	WO	99/15553		Robert Koch Instit	04/01/1999		
I.O.	9	EP	0984023		Japan Tobacco Inc.	03/08/2000		

Examiner Signature	<i>Ilion Auspessis</i>	Date Considered	10/26/2004
-----------------------	------------------------	--------------------	------------

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box

PTO/SB/08B (10-96)  
 Approved for use through 10/31/99. OMB 0651-0031  
 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
 Under the Paperwork Reduction Act of 1995, persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

## Complete if Known

Application Number NA 04/989,545  
 Filing Date 11/20/2001  
 First Named Inventor Sophie Lehar et al  
 Group Art Unit 1644  
 Examiner Name Ilia Anspenski  
 Attorney Docket Number MPI1998-067CP2CN1A(M)

## OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
I.O.	11	ROBINSON ET AL., "Predominant TH2-Like Bronchoalveolar T-Lymphocyte Population in Atopic Asthma," The NE Journal of Medicine, Vol. 326 (No. 5), p. 298-304, (January 30, 1993).	
	12	ROMAGNANI, S., "Induction of TH1 and TH2 Responses: A Key Role for the 'Natural' Immune Response?," Immunology Today, Elsevier Science Publishers Ltd. United Kingdom, Vol. 13 (No. 10), p. 379-381, (November 20, 1992).	
	13	DEL PRETE ET AL., "Allergen Exposure Induces the Activation of Allergen-specific Th2 Cells in the Airway Mucosa of Patients with Allergic Respiratory Disorder," European Jour of Immunology, p. 1445-1449, (November 20, 1993).	
	14	TAO ET AL., "Strength of TCR Signal Determines the Costimulatory Requirements for Th1 and Th2 CD4+ T Cell Differentiation," The Jour of Immunology, p. 5956-5963, (November 20, 1997).	
	15	NICOLAIDES ET AL., "Interleukin 9: A Candidate Gene for Asthma," Proc. Natl. Acad. Sci., p. 13175-1318, (November 20, 1997).	
	16	MORIGGL ET AL., "Activation of STAT Proteins and Cytokine Genes in Human Th2 and Th2 Cells Generated in the Absence of IL-12 and IL-4," The Jour of Immunology, p. 3385-3392, (November 20, 1998).	
	17	PADRID ET AL., "CTLA4Ig Inhibits Airway Eosinophilia and Hyperresponsiveness by Regulating the Development of Th1/Th2 Subsets in a Murine Model of Asthma," Amer Jour of Respiratory Cell and Molecular Biology, p. 453-462, (November 20, 1998).	
	18	SMITH ET AL., "Partial TCR Signals Delivered by FcR-Nonbinding Anti-CD3 Monoclonal Antibodies Differentially Regulate Individual Th Subsets," The Jour of Immunology, p. 4841-4849, (November 20, 1998).	
	19	DATABASE GENBANK ON STN ACCESSION NO. AA21744, MARRA ET AL., T WASH U-HHMI MOUSE EST PROJECT, " (January 21, 1997).	
I.O.	20	HUANG, S-K, "Molecular Modulation of Allergic Responses," J. Allergy Clin. Immunol., p. 887-892, (December 20, 1998).	
	21	<del>GAP Alignment of h1419 vs. V59728 in WO 98/39448</del>	

Examiner Signature

*Ilia Anspenski*

Date

Considered

10/26/2004

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box ☐

PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	11A 04/989,545
		Filing Date	11/20/2001
		First Named Inventor	Sophie Lehar et al
		Group Art Unit	1644
		Examiner Name	Lia Anzures
		Attorney Docket Number	MPI1998-067CP2CN1 (M)
Sheet 2	of 2		

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
I.O.	22	HUTLOFF, A. ET AL, "ICOS is an inducible T-Cell co-stimulaor structurally and functionally related to CD28," Nature, p. 263-266, ( January 21, 2000).	
	23	BUONFIGLIO, D. ET AL, "The T Cell Activation Molecule H4 and the CD28-Like Molecule ICOS are Identical," Eur. J. Immunol., p. 3463-3467, ( November 20, 2000).	
	24	BUONFIGLIO, D. ET AL., "Characterization of a Novel Human Surface Molecule Selectively Expressed by Mature Thymocytes, Activated T Cells and Subsets of T Cell Lymphomas," Eur. J. Immunol., p. 2863-2874, ( November 20, 1999).	
	25	REDOGLIA, V., ET AL., "Characterization of H4: A Mouse T Lymphocyte Activation Molecule Functionally Associated with the CD3/T Cell Receptor," Eur. J. Immunol., p. 2781-2789, ( November 20, 1996).	
	26	GONZALO, J. ET AL., "ICOS is Critical for T Helper Cell-Mediated Lung Mucosal Inflammatory Responses," Nature Immunology, Vol. 2 ( No. 7), p. 597-604, ( July 20, 2001).	
	27	ROTTMAN, J. ET AL., "The Costimulatory Molecule ICOS Plays an Important Role in the Immunopathogenesis of EAE," Nature Immunology, Vol. 2 ( No. 7), p. 605-611, ( July 20, 2001).	
I.O.	28	OZKAYNAK, E. ET AL., "Importance of ICOS-B7RP-1 Costimulation in Acute and Chronic Allograft Rejection," Naure Immunology, Vol. 2 ( No. 7), p. 591-596, ( July 20, 2001).	

Examiner Signature	Lia Anzures	Date Considered	10/26/2004
--------------------	-------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.